Publications by authors named "S Banuprakash Goud"
Article Synopsis
- Researchers developed coamorphous systems (CAM) using lumefantrine (LMF) and alpha-ketoglutaric acid (KGA) to improve LMF's solubility and bioavailability through three distinct methods: liquid-assisted grinding, solvent evaporation, and quench-cooling.
- Testing via PXRD, DSC, and other techniques confirmed the successful amorphization and intermolecular interactions in these CAMs, along with simulations showing diverse molecular environments.
- The new CAMs significantly enhanced solubility (up to 14.73x), dissolution rates (up to 2.63x), and pharmacokinetics in living organisms (up to 10.86x), while also demonstrating anti-cancer
Background And Objectives: Parkinson's disease (PD) is a neurodegenerative disorder involving depletion of dopaminergic neurons. Pathogenetic mechanisms leading to striatonigral degeneration are debatable. Chronic inflammation is proposed as one of the mechanisms.
View Article and Find Full Text PDFArticle Synopsis
- The study compared 5th and 7th generation bonding agents to evaluate their effectiveness in preventing microleakage from a fluoride sealant in 40 extracted human premolar teeth.
- Teeth were divided into two groups: one used a 5th generation bonding agent, while the other used a 7th generation agent, both treated with the same sealant.
- Results indicated that the 5th generation agent had more microleakage, but the difference was not statistically significant; the 7th generation agent showed less microleakage and was easier to apply.
Background: Standard neoadjuvant chemotherapy for locally advanced esophageal or gastroesophageal junction squamous cancer, 5-fluorouracil plus platinum, is toxic and logistically challenging; alternative regimens are needed.
Methods: This was a phase III randomized open-label noninferiority trial at Tata Memorial Center, India, in resectable locally advanced esophageal or gastroesophageal junction squamous cancer. Patients were randomly assigned 1:1 to 3 cycles of 3-weekly platinum (cisplatin 75 mg/m2 or carboplatin area under the curve 6) with paclitaxel 175 mg/m2 (day 1) or 5-fluorouracil 1000 mg/m2 continuous infusion (days 1-4), followed by surgery.
Article Synopsis
- No definitive studies previously showed that chemotherapy improved overall survival in advanced esophageal cancer, prompting a Phase III randomized trial comparing best supportive care (BSC) alone to BSC plus weekly paclitaxel.
- The trial involved 281 patients, revealing that those on chemotherapy experienced a median overall survival of 9.2 months, compared to only 4.2 months for those on BSC.
- Results showed that chemotherapy significantly improved response rates, progression-free survival, and quality of life, while not increasing severe toxicities, marking it as a valuable treatment option in this population.